Research programme: Leishmaniasis vaccine - Etna Biotech/NIAID
Alternative Names: Visceral leishmaniasis vaccine - Etna Biotech/NIAID; VL vaccine - Etna Biotech/NIAIDLatest Information Update: 28 May 2019
At a glance
- Originator Etna Biotech; National Institute of Allergy and Infectious Diseases
- Class Leishmaniasis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Visceral leishmaniasis
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Visceral-leishmaniasis(Prevention) in Italy
- 28 May 2019 No recent reports of development identified for research development in Visceral-leishmaniasis(Prevention) in USA
- 23 Apr 2015 Etna Biotech and NIAID agree to co-develop vaccine in USA for Leishmaniasis (Prevention)